myirislogo
24 October, 2019 01:57 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Infosys 650.75 1.16
Tata Motors 132.65 0.57
Tata Power 60.80 2.62
Adani Ports 396.25 5.85
State Bank O 275.50 1.87
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Panacea Biotec Limited
Panacea Biotec Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:531349NSE:PANACEABIOBloomberg:PNCB@INReuters:PNCA.BO
Market Lot: 1Face Value: 1ISIN Demat: INE922B01023
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
28-AUG-18 Panacea Biotec has entered into a tripartite agreement with Natco Pharma (Natco) and Breckenridge Pharmaceutical Inc. (Breckenridge) for the manufacture and supply of Azacitidine Injection for the U.S. market under Breckenridge's already-approved ANDA. Azacitidine is a generic equivalent of Vidaza??, which is marketed by Celgene Corporation, U.S. 12-MAR-18 Panacea Biotec announced the receipt of Establishment Inspection Report (EIR) ...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Panacea Biotec receives EIR for oncology manufacturing facility  -IRIS 12-Mar-18
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2016(12)31-Mar-2015(12)31-Mar-2014 (12)
Net sales 6353.406432.404671.40
Other Income255.60280.60116.40
Total Income6609.006713.004787.80
Cost of goods sold5521.106129.005975.20
OPBDIT1087.90584.00-1187.40
PAT8.70-652.30-4.20
Gross Block---
Equity capital61.3061.3061.30
EPS (Rs.)---0.07
DPS (Rs.)---
BV (Rs.)---
P/E range (x)--NA
Debt / Equity (x)---
Operating margin (% of OI)16.5 8.7-24.8
Net margin (% of OI) 0.1-9.7-0.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Ambala - Chandigarh Highway
Lalru
Punjab-140 501
PHONE
(01762) 505 90
FAX
(01762) 5059 06/ 09
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer